Is an innovative screening, diagnosis and monitoring tool for a
COMPLETE LIVER EVALUATION
and primary liver cancer prevention

Fibronostics Secures Financing,
announces new CEO

LIVERFASt™
for NAFLD, NASH,
HCV, HBV, Cirrhosis.

Help quantify and monitor liver damage in subjects with metabolic risk and fatty liver as well with viral hepatitis.

Fibronostics listed in the top 300
promising AI-driven companies
in life science

Uniquely Positioned among Noninvasive technologies

A combination of broadly available biomarkers and neural network-based AI provides a diagnostics accuracy equivalent to biopsy.

Fibronostics patent technology

Patented Technology

CPT Code: 0166U

Fibronostics CE mark

CE mark

(Conformité Européenne)

Fibronostics patent technology

AI Technology-based

Complete Liver Diagnosis

LIVERFASt™ – from Early Stage to Late Stage
for NAFLD, NASH Cirrhosis that provides prognosis for liver-related hard outcomes including HCC

Fibronostics Screening

Screening

Risk stratification among large patient populations allows for better management leading to cost reductions.

Fibronostics Diagnosis

Diagnosis

Noninvasive disease detection means earlier diagnosis and earlier intervention for better patient outcomes.

Fibronostics Monitoring

Monitoring

Regular surveillance with easily repeatable noninvasive diagnostics enables optimized disease management.

Noninvasive solutions for diagnosis, screening and monitoring.